At ImmuniMed, we are redefining the future of disease treatment with our groundbreaking Oral Dose Antibody Therapy. Unlike conventional vaccines that stimulate the host’s immune system to produce antibodies, our innovative approach delivers ready-made, target-specific antibodies directly to the host via oral administration. These antibodies are designed to inhibit or combat disease at its source, offering a safe, effective, and convenient alternative to traditional therapies.

Our antibodies are derived from chicken eggs, a natural and widely consumed component of the human diet. This unique production method ensures that our treatments are Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, making them both accessible and reliable.

Clinical Development: Advancing Human Health

ImmuniMed is currently conducting a Phase II clinical study in Calgary and Winnipeg, recruiting patients with mild to moderate Clostridioides difficile (C. diff) infections. This study aims to determine the optimal dosage and clinical efficacy of our egg-derived antibody therapy, IM-01 (Learn more at ClinicalTrials.gov NCT04121169).

The safety and effectiveness of our Oral Dose Therapeutic Antibody treatment have already been demonstrated in compassionate-use clinical studies across Canada, the USA, and Australia. In these studies, 106 C. diff-infected patients were treated with IM-01 under the care of four gastroenterologists and one infectious disease specialist. The results were remarkable:

• 94% of patients showed significant clinical improvement and negative stool test results.

• No disease relapses were reported during a 6-week follow-up period.

Building on this success, we are now expanding our clinical trials to demonstrate the efficacy of our therapy in preventing C. difficile infections.

Proven Efficacy in Animal Agriculture

Our oral antibody technology has already made a significant impact in animal agriculture. Licensed and approved by the Canadian Center for Veterinary Biologics, our antibody-based products are used to:

• Prevent diarrhea caused by Enterotoxigenic E. coli in pigs and calves.

• Improve growth performance in livestock.

This marks the first time in the world that an antibody-based product has been granted regulatory approval for use as a Veterinary Biologic, showcasing the versatility and scalability of our platform.

Research and Innovation

ImmuniMed is committed to advancing the science of antibody therapy. One of our key research projects demonstrated the effectiveness of orally administered antibodies in targeting Cryptosporidium parvum, a parasite that causes severe gastrointestinal illness. In preclinical studies, our treatment:

• Significantly reduced disease burden and parasite load.

• Improved survival rates in infected mice.

This research underscores the potential of our platform to address a wide range of infectious diseases, including those affecting vulnerable populations such as children.

Intellectual Property and Strategic Advantages

ImmuniMed’s innovative approach is backed by a robust portfolio of patents and intellectual property, including:

• US Patent #10513552 B2: Use of Polyclonal Antibodies Against Clostridium difficile for Treatment of Inflammatory Bowel Disease.

• US Patent #9873732: Polyclonal Antibodies Against Clostridium difficile and Uses Thereof.

• European Patent #EP2957570 and Canadian Patent #CA2895217: Polyclonal Antibodies Against Clostridium difficile and Uses Thereof.

Our technology offers several strategic advantages:

• Safety: Proven safe in both animal and human studies, with egg-derived antibodies recognized as GRAS by the FDA.

• Efficacy: Demonstrated clinical efficacy in treating C. diff infections and preventing gastro-enteric illnesses in animals.

• Scalability: Established large-scale production capabilities for egg-derived therapeutic antibodies.

Leadership Team

ImmuniMed is led by a team of seasoned experts with decades of experience in biotechnology, immunology, and business development:

• Dr. Pradip Maiti, M.Sc., Ph.D.: A renowned researcher and business leader with over 40 years of experience in microbiology and immunology. Dr. Maiti holds more than 20 patents in antibody therapy and has a proven track record of bringing innovative therapies to market.

• John Hare, MBA: A Winnipeg-based entrepreneur with over 35 years of experience in the livestock nutrition and biotech industries. John’s leadership has been instrumental in scaling ImmuniMed’s operations and driving commercialization efforts.

Join Us in Transforming Health

ImmuniMed is at the forefront of a new era in biotechnology, leveraging the power of targeted oral antibodies to address some of the most pressing health challenges of our time. From treating infectious diseases to improving animal health, our platform has the potential to make a lasting impact on global health.

Explore our science, discover our pipeline, and join us in shaping the future of medicine.